Clopidogrel drug interactions

Drug interactions Caution is called for when administering tenecteplase with drugs that affect platelet function such as aspirin, dipyridamole, clopidogrel, and glycoprotein Ilb/IIIa inhibitors. Administration of tenecteplase before, during, or after any of these drugs may increase the risk of... 

Lau WC. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation a new drug-drug interaction. Circulation 2003 107 32-7. 

Lau WC, Carville DG, Bates ER. Clinical significance of the atorvastatin-clopidogrel drug-drug interaction. Circulation 2004 I I0 e66-e67 author reply e66-e67. 

There are no documented drug interactions, but garlic s antiplatelet effect might be dangerous in patients taking warfarin or antiplatelet agents such as aspirin, clopidogrel, ticlopidine, or dipyridamole. 

Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 180(7) 713—718. 

Morais J, on behalf of die CAPRIE investigators. Use of concomitant medications in the CAPRIE trial clopidogrel is unlikely to be associated with clinically significant drug interactions. Eur Heart J 99%) 19 (Absttact Suppl) 5. 

Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hc p AS, Tait AR, Carville DGM, Guyer KE, Bates ER. Atorvastatin reduces die ability of clopidogrel to inhibit platelet aggregation. A new drug-drug interaction. Circulation ( 3) 107,32-7. 

Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother 2009 43(7) 1266-74. 

Floyd JS, Kaspera R, Marciante KD, Weiss NS, Heckbert SR, Lumley T, et al. A screening study of drug-drug interactions in cerivastatin users an adverse effect of clopidogrel. Clin Pharmacol Ther 2012,-91(5) 896-904. 

Bhurke SM, Martin BC, Li C, Franks AM, Bursae Z, Said Q. Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. Pharmacotherapy 2012 32 809-18. 

Cilostazol is a PDE3 inhibitor and also is a drug with multiple mechanisms of action (23,24), some of which are directly platelet-related, and others of which exert their effects indirectly via endothelial cells (Figs, 4 and 5), As a PDE inhibitor, it increases the concentration of cyclic nucleotides within platelets and inhibits platelet aggregation in response to shear forces (via ADP) and a variety of agonists. Like other inhibitors of platelet activation, it blocks the expression and release of P-selectin, a key adhesion molecule on the membrane of platelet alpha granules that externalizes with activation, and plays an important role in the interactions between platelets, endothelial cells, and leukocytes, The effect of cilostazol on P-selectin expression appears to be additive to those of aspirin and clopidogrel (25). 

---